Medicinal composition for treating diabetes hepatic fibrosis

A liver fibrosis and composition technology, which is applied in the field of traditional Chinese medicine or medicinal chemistry, can solve the problems of compound medicines with many flavors, complex components, influence on application, etc., and achieves the effect of good inhibition effect and proliferation inhibition effect.

Active Publication Date: 2014-06-18
INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, it has been reported in the literature that traditional Chinese medicine compound can improve the occurrence of liver fibrosis, but the compound has many medicinal flavors, generally more than 3 flavors, complex ingredients and unsatisfactory effect
At present, there are also reports about ursolic acid being used in the treatment of animal models of liver fibrosis, but its therapeutic effect is not very satisfactory, and when the concentration of ursolic acid is high, it is more toxic to liver cells, which affects its clinical application. Apply on

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating diabetes hepatic fibrosis
  • Medicinal composition for treating diabetes hepatic fibrosis
  • Medicinal composition for treating diabetes hepatic fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Example 1: Establishment of primary rat hepatic stellate cell proliferation model

[0056] 1. Reagents and Cells

[0057] Male Wistar rats, about 400 g, were provided by the Experimental Animal Center of the Academy of Military Medical Sciences.

[0058] 96-well plate, Corning; Type Ⅳ collagenase, sigma company; Pronase E, Roche company; Dnase Ⅰ, Roche company; DMEM medium, Tianrun Shanda Biotechnology Co., Ltd.; Heparin sodium, Sinopharm Chemical Reagent Co., Ltd.; PDGF-BB, Peprotech Corporation.

[0059] Peristaltic pump, Baoding Lange Constant Flow Pump Co., Ltd.; multi-head cell sample collector, Zhejiang Shaoxing ZT-2 type; liquid scintillation counter, PerkinElmer Company, model: 1450-024.

[0060] 2. Experimental steps

[0061] Primary rat hepatic stellate cells were isolated by in situ perfusion (Jiang Tao, Liang Liwu, Guo Shungen, et al. Isolation and culture of hepatic stellate cells. Journal of Armed Police Medical College, 2001,11(1):7.), according to ...

Embodiment 2

[0067] Example 2: Toxic effect of ursolic acid and Schisandrin B alone on primary hepatocytes

[0068] 1. Experimental materials

[0069] Thiazolyl blue tetrazolium bromide (MTT), Amreaco Company; Ensipire multifunctional microplate reader, PerkinElmer, model: 2300; other reagent sources are the same as in Example 1.

[0070] Ursolic acid and Schizandrin B can be purchased commercially (for example, purchased from Shanghai Tongtian Biotechnology Co., Ltd., the article numbers are E-0076 and E-0133, and the purity is greater than 97%), or refer to the methods of the following examples 8-9 preparation.

[0071] 2. Experimental steps

[0072]The toxic effects of ursolic acid and schisandrin B alone on primary hepatocytes were observed by MTT method. Separation of primary rat hepatocytes by in situ perfusion (Lao Quanlin, Jiang Qingyan, Gao Shujing, etc. Separation of rat hepatocytes by in situ perfusion. Journal of South China Agricultural University (Natural Science Edition...

Embodiment 3

[0076] Embodiment 3: Ursolic acid and Schizandrin B are used alone and in combination on primary HSC Effects on DNA Synthesis

[0077] 1. Reagents and Cells

[0078] Ursolic acid and Schizandrin B can be purchased commercially (for example, purchased from Shanghai Tongtian Biotechnology Co., Ltd., the article numbers are E-0076 and E-0133, and the purity is greater than 97%), or refer to the methods of the following examples 8-9 preparation.

[0079] 2. Experimental method and steps

[0080] use 3 The effects of ursolic acid and schisandrin B on DNA synthesis in hepatic stellate cells were observed by H-TdR incorporation. Primary rat hepatic stellate cells were isolated by in situ perfusion method, and the ratio of 1×10 5 Inoculate in a 96-well plate at a density of 1 / ml, and the medium is DMEM high-glucose medium containing 20% ​​FBS, 37°C, 5% CO 2 Cultivate in the incubator for 24 hours, replace with DMEM high-glucose medium containing 0.5% FBS, 37°C, 5% CO 2 After...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of traditional Chinese medicines or the pharmaceutical chemistry, and relates to a medicinal composition for resisting hepatic fibrosis and/or hepatic cirrhosis. The medicinal composition includes ursolic acid and schisandrin B. The invention also relates to a use of the medicinal composition in the preparation of medicines for treating and/or preventing and/or adjunctively treating hepatic fibrosis and hepatic cirrhosis, or medicines for inhibiting hepatic stellate cell proliferation or inhibiting hepatic stellate cell DNA synthesis, and a method for inhibiting hepatic stellate cell proliferation or inhibiting hepatic stellate cell DNA synthesis. The medicinal composition can obviously improve the hepatic fibrosis degree, has the advantages of few components, strong effect, simple preparation, no obvious hepatotoxicity, and good market prospect, and is of certain practical significance for promoting traditional Chinese medicinal modernization.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicine or medicinal chemistry, and relates to a pharmaceutical composition for preventing and treating liver fibrosis and / or liver cirrhosis. The present invention also relates to the use of the pharmaceutical composition in the preparation of medicines for treating and / or preventing and / or assisting the treatment of liver fibrosis and / or cirrhosis, or medicines for inhibiting proliferation of hepatic stellate cells or DNA synthesis of hepatic stellate cells , and a method of inhibiting hepatic stellate cell proliferation or inhibiting hepatic stellate cell DNA synthesis. Background technique [0002] Hepatic fibrosis is a pathological change in which excessive deposition of extracellular matrix in the liver leads to abnormal liver structure or (and) function. It is a common pathological change in many advanced chronic liver diseases and is the precursor stage of liver cirrhosis. The etiology...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/56A61K31/36A61K36/74A61P1/16
Inventor 张永祥周文霞肖智勇迟莉
Owner INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap